These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 18296421)

  • 21. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.
    McKeage K; Lyseng-Williamson KA
    Pharmacoeconomics; 2008; 26(8):699-719. PubMed ID: 18620462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
    Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
    Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chinese HER2 positive early breast cancer trastuzumab adjuvant therapy: preliminary outcomes].
    Zhang P; Yu SY; Shen ZZ; Song ST; Guan ZZ; Jiao SC; Zheng S; Xu GW; Feng FY
    Zhonghua Yi Xue Za Zhi; 2012 Dec; 92(47):3345-9. PubMed ID: 23328596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients.
    Yamshiro H; Iwata H; Masuda N; Yamamoto N; Nishimura R; Ohtani S; Sato N; Takahashi M; Kamio T; Yamazaki K; Saito T; Kato M; Lee T; Ohno S; Kuroi K; Takano T; Takada M; Yasuno S; Morita S; Toi M
    Int J Clin Oncol; 2015 Aug; 20(4):709-22. PubMed ID: 25666483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
    Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
    Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
    Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
    de Nonneville A; Gonçalves A; Zemmour C; Classe JM; Cohen M; Lambaudie E; Reyal F; Scherer C; Muracciole X; Colombo PE; Giard S; Rouzier R; Villet R; Chopin N; Darai E; Garbay JR; Gimbergues P; Sabiani L; Coutant C; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Breast Cancer Res Treat; 2017 Apr; 162(2):307-316. PubMed ID: 28155054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials.
    Chen L; Zhou W; Hu X; Yi M; Ye C; Yao G
    Cancer Treat Rev; 2019 May; 75():12-19. PubMed ID: 30856373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
    Strasser-Weippl K; Horick N; Smith IE; O'Shaughnessy J; Ejlertsen B; Boyle F; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Rappold E; Finkelstein DM; Goss PE
    Breast Cancer Res; 2015 Apr; 17(1):56. PubMed ID: 25888246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
    Jahanzeb M
    Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.
    Skedgel C; Rayson D; Younis T
    Value Health; 2009; 12(5):641-8. PubMed ID: 19490562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials.
    Gyawali B; Niraula S
    Cancer Treat Rev; 2017 Nov; 60():18-23. PubMed ID: 28863313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Breast cancer: HER2 changes one's cards on the table].
    Lopez M
    Clin Ter; 2005; 156(5):255-62. PubMed ID: 16382976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2 and hormone receptor-positive breast cancer--blocking the right target.
    Cortés J; Saura C; Bellet M; Muñoz-Couselo E; Ramírez-Merino N; Calvo V; Pérez J; Vidal M
    Nat Rev Clin Oncol; 2011 May; 8(5):307-11. PubMed ID: 21151204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
    Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
    Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.